Recursion's AI-Powered Drug Revolution Recursion is a clinical-stage TechBio company that is fundamentally built upon the principles of artificial intelligence and machine learning.

Recursion, whose advisers include AI pioneer Yoshua Bengio, will use its biological and chemical datasets exceeding 23,000 terabytes to train AI models on Nvidia's cloud platform. Nvidia, seen as ...

Is Recursion Pharmaceuticals stock a buy? Does any of this change the premise for buying Recursion Pharmaceuticals stock? Not really. The company's technology is promising.